Antiretroviral drug toxicity -- a challenge for the hepatologist? (Q34519467)

2 August 2017

1 reference

title

Antiretroviral drug toxicity -- a challenge for the hepatologist? (English)

1 reference

2 August 2017

anti-retroviral agent

0 references

author name string

Ulrich Spengler

series ordinal

1

1 reference

PubMed ID

11830343

2 August 2017

Mathias Lichterfeld

series ordinal

2

1 reference

PubMed ID

11830343

2 August 2017

Jürgen Kurt Rockstroh

series ordinal

3

1 reference

2 August 2017

1 February 2002

1 reference

2 August 2017

Journal of Hepatology

1 reference

2 August 2017

36

1 reference

2 August 2017

2

1 reference

2 August 2017

283-294

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Analysis of the Discontinuation of Protease Inhibitor Therapy in Routine Clinical Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Criteria of drug-induced liver disorders. Report of an international consensus meeting

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Mitochondrial toxicity of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatotoxicity due to mitochondrial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatic steatosis: innocent bystander or guilty party?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Mitochondria in steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Mitochondria as regulators of apoptosis: doubt no more.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Severe hepatic failure related to nevirapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Stavudine selectively induces apoptosis in HIV type 1-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Lactic acidosis associated with stavudine administration: a report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Adverse effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Nevirapine-associated Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Severe hepatitis in three AIDS patients treated with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatotoxicity associated with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Mechanism of indinavir-induced hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Drug interactions of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Pharmacokinetic interaction between ritonavir and clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Indinavir-associated hepatitis in patients with advanced HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Riboflavin to treat nucleoside analogue-induced lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900311-7

7 January 2021

10.1016/S0168-8278(01)00311-7

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11830343